Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > VP1

VP1

Brief Information

Name:Capsid protein
Target Synonym:Capsid Proteins,Viral Capsid proteins
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:27
Lastest Research Phase:Approved

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
VP1-A5147 Adeno-associated virus 9 AAV9 VP1, Recombinant Protein
VP1-A5147-structure
VP1-A5147-sds
VP1-A5146 Adeno-associated virus 8 AAV8 VP1, Recombinant Protein
VP1-A5146-structure
VP1-A5146-sds
VP1-A5145 Adeno-associated virus 6 AAV6 VP1, Recombinant Protein
VP1-A5145-structure
VP1-A5145-sds
VP1-A5144 Adeno-associated virus 5 AAV5 VP1, Recombinant Protein
VP1-A5144-structure
VP1-A5144-sds
VP1-A5143 Adeno-associated virus 2 AAV2 VP1, Recombinant Protein
VP1-A5143-structure
VP1-A5143-sds
ACRO Quality

Part of Bioactivity data

VP1-A5143-ELISA
 VP1 ELISA

Immobilized AAV2 VP1, Recombinant Protein (Cat. No. VP1-A5143) at 1 μg/mL (100 μL/well) can bind Anti-AAV,VP1+VP2+VP3,B1 Mouse Monoclonal,Purified,IgG1 with a linear range of 1-31 ng/mL (QC tested).

Synonym Name

capsid protein

Background

Norovirus is one of the leading causes of non-bacterial acute gastroenteritis which affects millions of people all over the world. Norovirus has a variety of genotypes with the GII.4 dominating the recent norovirus outbreaks. Besides GII.4, GI.1 is also important for research on Norovirus as it is the original genotype of Norovirus. The capsid protein VP1 is the target for vaccine and antibody development and an Anti-VP1 (NoV)-antibody-5I2 was found to be able to interact with the VP1, serving as a receptor for it.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Lenacapavir sodium GS-6207 Approved Gilead Inc SUNLENCA EU HIV Infections Gilead Sciences Ireland Uc 2022-08-17 HIV Infections Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Morphothiadine Mesylate GLS4JHS; GLS-4 Phase 3 Clinical South China Center For Innovative Pharmaceuticals, Guangdong Dongyangguang Pharmaceutical Co Ltd Hepatitis B, Chronic; Hepatitis B Details
GS-1720/GS-4182 GS-1720/GS-4182 Phase 3 Clinical Gilead Sciences Inc HIV Infections Details
Bictegravir/Lenacapavir sodium Phase 3 Clinical Gilead Sciences Inc HIV Infections Details
GS-4182 GS-4182 Phase 3 Clinical Gilead Sciences Inc HIV Infections Details
Lenacapavir/Islatravir MK-8591D Phase 3 Clinical Merck & Co Inc, Gilead Sciences Inc HIV Infections Details
Azodicarbonamide HPH-116; NSC-674447 Phase 2 Clinical H-Phar Pharmaceuticals HIV Infections Details
QL-007 QL-007 Phase 2 Clinical Qilu Pharmaceutical Co Ltd Hepatitis B, Chronic Details
GST-HG141 GST-HG141 Phase 2 Clinical Fujian Cosunter Pharmaceutical Co Ltd Hepatitis B, Chronic; Hepatitis B Details
bersacapavir JNJ-56136379; JNJ-379; JNJ-6379; 14C JNJ-56136379 Phase 2 Clinical Johnson & Johnson Hepatitis, Chronic; Hepatitis B, Chronic; Renal Insufficiency; Hepatitis B; Hepatic Insufficiency Details
RO-7049389 RO-7049389 Phase 2 Clinical F. Hoffmann-La Roche Ltd Hepatitis B, Chronic Details
Traxivitug MAU-868 Phase 2 Clinical Novartis Pharma Ag BK Polyomavirus Infections; Polyomavirus Infections Details
Vebicorvir ABI-H0731; ABIH-0731 Phase 2 Clinical Indiana University Hepatitis B, Chronic; Hepatitis B Details
Canocapavir ZM-H1505R; CB-001; CB-01 Phase 2 Clinical Shanghai Zhimeng Biopharma Inc Hepatitis B, Chronic; Hepatitis B Details
VH-4011499 VH-4011499; GSK-4011499; VH-4011499-A; VH-499 Phase 2 Clinical Viiv Healthcare HIV Infections Details
VH-4004280 VH-4004280; VH 4004280A Phase 2 Clinical Viiv Healthcare HIV Infections Details
Firzacorvir 2158; ABI-2158; ABI-H2158 Phase 2 Clinical Assembly Biosciences Inc, Indiana University Hepatitis B, Chronic Details
BIT-225 BIT-225 Phase 2 Clinical Biotron HIV Infections; Hepatitis C Details
Fipravirimat BMS-986197; GSK-3640254 Phase 1 Clinical Bristol-Myers Squibb Company HIV Infections Details
AB-423 AB-423 Phase 1 Clinical Arbutus Biopharma Corp Hepatitis B Details
H-05(Protheragen) Phase 1 Clinical Protheragen Inc Hepatitis B Details
EV68-228-N EVD68-228N; EVD68-228-N; EV68-228-N; KB-13-A Phase 1 Clinical National Institute Of Allergy And Infectious Diseases (Niaid), KBio Inc Enterovirus Infections; Acute Flaccid Myelitis Details
PLD-401 PLD-401 Phase 1 Clinical Pelemed Co Ltd Hepatitis B, Chronic Details
Morphothiadine Mesylate/Ritonavir Phase 1 Clinical Guangdong Dongyangguang Pharmaceutical Co Ltd Hepatitis B, Chronic Details
LW-231 LW-231 Phase 1 Clinical Shanghai Longwood Biopharmaceuticals Co Ltd Hepatitis B, Chronic Details
ALG-010184 ALG-010184 Phase 1 Clinical Aligos Therapeutics Inc Hepatitis B, Chronic Details
ALG-000184 ALG-000184 Phase 1 Clinical Aligos Therapeutics Inc Hepatitis B, Chronic Details
XT-1061 XTYW-001; XTYW001; XT-1061; XT1061 Phase 1 Clinical Xi'an Xintong Pharmaceutical Research Co Ltd Hepatitis B, Chronic Details
GS-CA2 GS-CA2; GS-CA-2 Phase 1 Clinical Gilead Sciences Inc HIV Infections Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message